Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | August 04, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date August 04, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-04 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-04 · Exercise / conversion · Acquired 87,373 · Balance 87,373 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Row 2 · 2026-08-04 · Exercise / conversion · Acquired 27,567 · Balance 114,940 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Row 3 · 2026-08-04 · Exercise / conversion · Acquired 23,364 · Balance 138,304 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Row 4 · 2026-08-04 · Exercise / conversion · Acquired 20,491 · Balance 158,795 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Row 5 · 2026-08-04 · Sale · Disposed 158,795 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F2: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2031-08-01 | Direct | 0 |
Reported balance
After 2026-08-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-04 · Exercise / conversion · Disposed 87,373 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.28 · Expires 2033-02-23 | Direct | 0 |
Reported balance
After 2026-08-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-04 · Exercise / conversion · Disposed 27,567 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.85 · Expires 2034-02-13 | Direct | 0 |
Reported balance
After 2026-08-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-04 · Exercise / conversion · Disposed 23,364 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2035-02-06 | Direct | 0 |
Reported balance
After 2026-08-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-04 · Exercise / conversion · Disposed 20,491 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 20,491 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · derivative · entry 9 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,491 shares Expires 2035-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 23,364 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · derivative · entry 8 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,364 shares Expires 2034-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 27,567 | $0.00 Strike: $25.28 | $0.00 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · derivative · entry 7 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,567 shares Expires 2033-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionStock Option (right to buy) · Derivative | 87,373 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · derivative · entry 6 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,373 shares Expires 2031-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F3 · derivative.exercise_date: All of the shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 158,795 | $60.21 | $9,561,586.85 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · nonDerivative · entry 5 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 20,491 | $22.47 | $460,432.77 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · nonDerivative · entry 4 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 23,364 | $14.85 | $346,955.40 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · nonDerivative · entry 3 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 27,567 | $25.28 | $696,893.76 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · nonDerivative · entry 2 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Read SEC document |
| August 04, 2026 Filed Aug 7, 2026 00:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | Exercise / conversionCommon Stock | 87,373 | $2.48 | $216,685.04 |
DisclosureSEC source: 0001865125-26-000004 · form4-08072026_120853.xml · nonDerivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:56 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 17,126 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001865125-26-000001 · form4-02182026_120255.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,126 Underlying: Common Stock · 17,126 shares Expires 2036-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:35 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 20,491 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003518 · form4-02102025_100228.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,491 Underlying: Common Stock · 20,491 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:48 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 16,835 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004014 · form4-02162024_010234.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,835 Underlying: Common Stock · 16,835 shares Expires 2034-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| February 13, 2024 Filed Feb 21, 2024 00:27 UTC Amendment | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 23,364 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004486 · form4a-02212024_120231.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,364 Underlying: Common Stock · 23,364 shares Expires 2034-02-13 F1 · shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F2 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. F1 · derivative.underlying_shares: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. F1 · balance_after: The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantEmployee Stock Option (right to buy) · Derivative | 87,373 | Not disclosed Strike: $2.48 | Not disclosed |
DisclosureSEC source: 0001209191-23-013500 · doc4.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,373 Underlying: Common Stock · 87,373 shares Expires 2031-08-02 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 13, 2022 (the "Merger Agreement"), by and among Imara Inc. ("Imara"), Enliven Therapeutics, Inc., ("Enliven") and Iguana Merger Sub, Inc., a wholly owned subsidiary of the Issuer (the "Merger Sub"), each Enliven stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Imara and became an option to acquire, on the same terms and conditions as were applicable to such Enliven stock option immediately prior to the effective time of the Merger, a number of shares of Imara common stock equal to the number of shares of Enliven common stock subject to the unexercised portion of the Enliven stock option immediately prior to the effective time of the Merger, multiplied by the exchange ratio of approximately 0.2951 shares of Imara common stock for each share of Enliven common stock (rounded down to the nearest whole share number), (footnote continued in footnote (3)) F3 · price: (continued from footnote (2)): with an exercise price per share for the options equal to the exercise price per share of such Enliven stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F1 · derivative.exercise_date: The shares underlying the option are subject to an early exercise provision and vest in 48 equal monthly installments beginning on September 2, 2021. Read SEC document |
| February 23, 2023 Filed Apr 7, 2023 00:17 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 27,567 | $0.00 Strike: $25.28 | $0.00 |
DisclosureSEC source: 0001209191-23-023664 · doc4.xml · derivative · entry 1 Derynck Mika K · CIK 0001865125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,567 Underlying: Common Stock · 27,567 shares Expires 2033-02-23 F1 · derivative.exercise_date: 1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.